Table 1 Baseline characteristics

Characteristic	N = 159	
Age-year		
Median	64	
Range	40-75	
Sex-no. (%)		
Male	126	(79)
Female	33	(21)
Smoking status		
Non or light smoker	25	(16)
Heavy smoker	119	(75)
Unknown	15	(9)
ECOG performance status-no. (%)		
0	90	(57)
1	67	(42)
2	2	(1)
Histology-no. (%)		
ad	84	(53)
sq	54	(34)
Other	21	(13)
Clinical stage-no. (%)		
IIIA	86	(54)
IIIB	73	(46)

Abbreviations: ECOG Eastern Cooperative Oncology Group, *ad* adenocarcinoma, *sq* squamous cell carcinoma.

Complete response was observed in 6 patients, and 107 patients had partial response. Then, ORR was 72% (95% confidence interval [CI]: 65–78). Figure 1 shows Kaplan-Meier curves of PFS and OS. Median PFS was 12 months (95% CI: 10–14), and median OS was 39 months (95% CI: 30–46). Among 110 first relapse sites, 29 were loco-regional, 66 were distant, and 15 were both. Of 114 relapsed patients, 89 (78%) received subsequent chemotherapy, and 58 (51%) received third line chemotherapy. Six patients had *epidermal growth factor receptor (EGFR)* mutation, and they all were treated with gefitinib in a subsequent line. Six other patients demonstrated durable progression-free intervals (≥ 6 months) with EGFR-tyrosine kinase inhibitors, but their *EGFR* mutation status could not be assessed for lack of a sufficient specimen.

Table 2 Treatment characteristics

Treatment	N = 159	
Chemothrapy regimen-no. (%)		
CBDCA + PTX	46	(29)
CDDP + S-1	46	(29)
CDDP + VNR	41	(26)
MVP	14	(9)
CBDCA + CPT-11	5	(3)
CDDP + VP-16	4	(2)
CDDP + VNR + DE-766	3	(2)
RT dose-Gy		
Median	60	
Range	52-74	

Abbreviations: CBDCA carboplatin, *PTX* paclitaxel, *CDDP* cisplatin, *VNR* vinorelbine, *MVP* mitomycin, vindesine, and cisplatin, *CPT-11* irinotecan, *VP-16* etoposide, *RT* radiation therapy.



Figure 1 Kaplan-Meier-estimated PFS (dashed line) and OS curve (bold line) in LA-NSCLC patients treated with concurrent CRT (n = 159).

One hundred and forty-eight, 138, 121, 106, 101, 93, 87, and 79 patients who were alive at 9, 12, 15, 18, 21, 24, 27, and 30 months were included in the respective landmark analysis. The hazard ratio (HR) of patients who achieved progression-free to those who progressed at each landmark analysis is described in Figure 2. HR gradually decreased in accordance with progression-free interval extended, and reached the lowest level at 24



Figure 2 Hazard ratio of landmark analysis at each time point. Dashed lines indicate 95% confidence intervals. Abbreviations: CR, complete response; PR, partial response.

months (0.11; 95% CI: 0.05-0.24). Figures 1 and 2 suggest that an observational period of about 24 months is sufficient to detect almost all recurrences.

Next, we examined the 5-year survival rates of patients who achieved response or progression-free at each time point. Among patients with complete response, or partial response, the 5-year survival rate was 45% (95% CI: 35–55) (Figure 3). The 5-year survival rates of patients who were progression free at each time point (3-months intervals from 9 to 30 months) were 53% (95% CI: 42–64), 69% (95% CI: 57–79), 75% (95% CI: 62–84), 82% (95% CI: 68–90), 84% (95% CI: 70–91), 89% (95% CI: 76–95), 90% (95% CI: 77–96), and 90% (95% CI: 77–96), respectively. The rate gradually increased in accordance with progression-free interval extended, and finally reached a plateau at 24 months. Patients who maintained progression-free intervals longer than 24 months had a 5-year survival rate of about 90%.

Discussion

In this study, 159 LA-NSCLC patients treated with concurrent CRT were analyzed to evaluate the surrogacy of ORR and PFS rate at 3-month intervals for the 5-year survival rate. Kaplan-Meier curve of progression-free survival (Figure 1) and HR of landmark analysis at each time point (Figure 2) suggest that most of progression occurred in the first 2 years. Patients who maintained progression-free intervals longer than 2 years had a 5-year survival rate of approximately 90%, and the rate did not increase thereafter (Figure 3).

Although ORR could be assessed in the early period of CRT, its surrogacy for the 5-year survival rate has not been fully evaluated. McAleer et al., did a combined analysis of two RTOG studies with CRT [13]. They reported that response to induction chemotherapy was a possible predictor of long survival (p = 0.06). Kim et al., also reported that responders demonstrated 5-fold long term survival compared with non-responders among LA-NSCLC patients treated with CRT [14]. However, in McAleer's report, Kaplan-Meier curves of OS revealed that 90% of responders died within 4 years. Furthermore, Kim's report was premature because the median follow-up time was only 489 days. Our analysis, with a longer follow up period, demonstrated that the ORR was not a favorable surrogate marker for the 5-year survival rate.



Figure 3 Five-year survival rates of patients who achieved each outcome. The bars indicate 95% confidence intervals.

With regard to median PFS, Mauguen et al., conducted a meta-analysis of LA-NSCLC. They found a very good correlation between median PFS and OS both at the individual level and trial level (ρ^2 range; 0.77-0.85, R2 range; 0.89-0.97, respectively) [15]. However, it is worth noting that their analysis contained relatively old trials. The median survival time of 15 months reported by Mauguen et al. was much shorter than that in a recent phase III trial, which reported a median survival time of 29 months [16]. This prolongation of survival may account for the development of post progression therapy, as the median PFS did not differ between the 2 reports. This might be a cause for concern about the relationship between median PFS and OS. In fact, our analysis showed that the 5-year survival rates in patients who were disease free at 9–12 months were only 53-69%. The rate gradually increased in accordance with progression-free interval extended, and reached a plateau at 90% after 24 months. This suggests that longer progression-free period, not median PFS, is required to identify cured patients.

The present study has several limitations. First, this study contained various chemotherapy regimens, and the timing of evaluatton depended on investigators because this was a retrospective study. Second, efficacy results were slightly better than previous reports. In our analysis, about 70% of patients were screened with PET (or PET-CT) at diagnosis, and 3-dimensional conformal radiation therapy was adopted in all cases. These contributed to accurate staging, and proper radiation therapy. In addition, the proportion of patients who received post progression therapy was very high (approximately 80%).

Conclusion

Our study suggests that PFS at 2 years could be a reliable surrogate endpoint for 5-year survival rate in LA-NSCLC patients treated with concurrent CRT. Further analysis is warranted using prospective datasets.

Competing interest

The authors declare that they have no competing interests.

Authors' contributions

HA contributed to the drafting of this manuscript and data collection, and KM, and TN contributed to the study design and statistical analysis. HI, TS, TT, HK, HM, ME, HH, TT, and NY contributed to analysis of the data and interpretation of the findings. All authors have read and approved of the submission of the final manuscript.

Acknowledgements
We thank Charles McKay who provided medical assistance.

Author details
[1]Division of Thoracic Oncology, Shizuoka Cancer Center, Shimonagakubo, 1007 Shimonagakubo, Nagaizumi-cho Sunto-gun, Shizuoka 411-8777, Japan. [2]Clinical Trial Management Department, Shizuoka Cancer Center, Shimonagakubo, Nagaizumi-cho Sunto-gun, Shizuoka, Japan. [3]Department of Respiratory Medicine, Juntendo University, Hongou Bunkyou-ku, Tokyo, Japan. [4]Division of Diagnostic Radiology, Shizuoka Cancer Center, Shimonagakubo, Nagaizumi-cho Sunto-gun, Shizuoka, Japan. [5]Division of Radiation Oncology, Shizuoka Cancer Center, Shimonagakubo, Nagaizumi-cho Sunto-gun, Shizuoka, Japan. [6]Third Department of Internal Medicine, Wakayama Medical University, Kimiidera, Wakayama, Japan.

Received: 2 September 2013 Accepted: 9 January 2014
Published: 14 January 2014

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: **Global cancer statistics.** *CA Cancer J Clin* 2011, **61**:69–90.
2. Govindan R, Bogart J, Vokes EE: **Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future.** *J Thorac Oncol* 2008, **3**:917–928.
3. Reinfuss M, Glinski B, Kowalska T, Kulpa J, Zawila K, Reinfuss K, Dymek P, Herman K, Skolyszewski J: **Radiotherapy for stage III, inoperable, asymptomatic small cell lung cancer. Final results of a prospective randomized study (240 patients).** *Cancer Radiother* 1999, **3**(6):475–479.
4. Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR, Turrisi A: **Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer.** *Chest* 2000, **117**:358–364.
5. Auperin A, Le Pe'choux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP: **Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer.** *J Clin Oncol* 2010, **28**:2181–2190.
6. O'Rourke N, Roqué I, Figuls M, Farré Bernadó N, Macbeth F: **Concurrent chemoradiotherapy in non-small cell lung cancer.** *Cochrane Database Syst Rev* 2010, **16**(6):CD002140.
7. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M: **Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non–small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.** *J Clin Oncol* 2010, **28**:3739–3745.
8. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M: **Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.** *J Clin Oncol* 2010, **28**:3299–3306.
9. Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, Saka H, Nishimura Y, Nakagawa K, Fukuoka M: **S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).** *J Thorac Oncol* 2011, **6**(12):2069–2075.
10. Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N: **Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.** *Cancer Sci* 2004, **95**(8):691–695.
11. Naito Y, Kubota K, Nihei K, Fujii T, Yoh K, Niho S, Goto K, Ohmatsu H, Saijo N, Nishiwaki Y: **Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer.** *J Thorac Oncol* 2008, **3**(6):617–622.
12. Nishimura Y, Harada H, Soejima T, Tsujino K, Hayakawa K, Kozuka T, Tanaka M, Sasaki T, Yamamoto N, Nakagawa K: **Phase II study of Nimotuzumab in combination with concurrent chemoradiation therapy (CRT) in patients with locally advanced Non-small Cell Lung Cancer (NSCLC).** *Int J Radiat Oncol Biol Phys* 2012, **84**(3):S68.
13. McAleer MF, Moughan J, Byhardt RW, Cox JD, Sause WT, Komaki R: **Does response to induction chemotherapy predict survival for locally advanced non-small cell lung cancer? Secondary analysis of RTOG 8804/8808.** *Int J Radiat Oncol Biol Phys* 2010, **76**(3):802–808.
14. Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H: **Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer.** *Lung Cancer* 2005, **50**:235–245.
15. Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S: **Surrogate Lung Project Collaborative Group. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.** *Lancet Oncol* 2013, **14**(7):619–626.
16. Bradley JD, Paulus R, Komaki R, Masters GA, Forster K, Schild SE, Bogart J, Garces YI, Narayan S, Kavadi V, Nedzi LA, Michalski JM, Johnson D, MacRae RM, Curran WJ, Choy H: **A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.** *J Clin Oncol* 2013, **31**(15):7501.

doi:10.1186/1471-2407-14-18
Cite this article as: Akamatsu *et al.*: Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. *BMC Cancer* 2014 **14**:18.

Hazama et al. Journal of Translational Medicine 2014, 12:108
http://www.translational-medicine.com/content/12/1/108

JOURNAL OF TRANSLATIONAL MEDICINE

RESEARCH Open Access

A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Shoichi Hazama[1*], Yusuke Nakamura[2], Hiroaki Tanaka[3], Kosei Hirakawa[3], Ko Tahara[4], Ryoichi Shimizu[5], Hiroaki Ozasa[5], Ryuichi Etoh[5], Fumiaki Sugiura[6], Kiyotaka Okuno[6], Takumi Furuya[7], Taku Nishimura[8], Koichiro Sakata[8], Kazuhiko Yoshimatsu[9], Hiroko Takenouchi[1], Ryouichi Tsunedomi[1], Yuka Inoue[1], Shinsuke Kanekiyo[1], Yoshitaro Shindo[1], Nobuaki Suzuki[1], Shigefumi Yoshino[1], Hirokazu Shinozaki[10], Akira Kamiya[10], Hiroyuki Furukawa[10], Takeharu Yamanaka[11], Tomonobu Fujita[12], Yutaka Kawakami[12] and Masaaki Oka[1]

Abstract

Background: We previously conducted a phase I trial for advanced colorectal cancer (CRC) using five HLA-A*2402-restricted peptides, three derived from oncoantigens and two from vascular endothelial growth factor (VEGF) receptors, and confirmed safety and immunological responses. To evaluate clinical benefits of cancer vaccination treatment, we conducted a phase II trial using the same peptides in combination with oxaliplatin-based chemotherapy as a first-line therapy.

Methods: The primary objective of the study was the response rates (RR). Progression free survival (PFS), overall survival (OS), and immunological parameters were evaluated as secondary objective. The planned sample size was more than 40 patients for both HLA2402-matched and -unmatched groups. All patients received a cocktail of five peptides (3 mg each) mixed with 1.5 ml of IFA which was subcutaneously administered weekly for the first 12 weeks followed by biweekly administration. Presence or absence of the HLA-A*2402 genotype were used for classification of patients into two groups.

Results: Between February 2009 and November 2012, ninety-six chemotherapy naïve CRC patients were enrolled under the masking of their HLA-A status. Ninety-three patients received mFOLFOX6 and three received XELOX. Bevacizumab was added in five patients. RR was 62.0% and 60.9% in the HLA-A*2402-matched and -unmatched groups, respectively ($p = 0.910$). The median OS was 20.7 months in the HLA-A*2402-matched group and 24.0 months in the unmatched group (log-rank, $p = 0.489$). In subgroup with a neutrophil/lymphocyte ratio (NLR) of < 3.0, patients in the HLA-matched group did not survive significantly longer than those in the unmatched group (log-rank, $p = 0.289$) but showed a delayed response.

Conclusions: Although no significance was observed for planned statistical efficacy endpoints, a delayed response was observed in subgroup with a NLR of < 3.0. Biomarkers such as NLR might be useful for selecting patients with a better treatment outcome by the vaccination.

Trial registration: Trial registration: UMIN000001791.

Keywords: Peptide vaccine, Peptide cocktail, Colorectal cancer, Phase II study, FOLFOX, Chemotherapy

* Correspondence: hazama@yamaguchi-u.ac.jp
[1]Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Japan
Full list of author information is available at the end of the article

Background

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death in industrialized countries [1]. In the past decade, a combination treatment of fluorinated-pyrimidine with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX, XELOX), with or without monoclonal antibodies such as anti-vascular endothelial growth factor (VEGF) antibody or anti-epidermal growth factor receptor (EGFR) antibody, has markedly improved the prognosis of patients with metastatic CRC (mCRC) [2-6]. However, most of the patients reveal progression of the disease due to chemo-resistance and lose their lives.

As an attempt to validate a new treatment modality to overcome the limited disease control status of mCRC, we conducted a combination treatment of five therapeutic epitope-peptides with chemotherapy. Recent developments in genome-based technologies have enabled us to obtain comprehensive gene expression profiles of malignant cells and compare them with normal cells [7]. We had previously identified three oncoantigens, RNF43 (ring finger protein 43) [8], 34 kDa translocase of the outer mitochondrial membrane (TOMM34) [9], and KOC1 (IMP-3; IGF-II mRNA binding protein 3) [10], as targets for the development of cancer peptide vaccines for CRC.

Although immunotherapy using tumor infiltrating cells (TIL) or vaccine treatment are promising modalities for the treatment of cancer, recent reports have indicated several mechanisms in tumor tissues which make cancer cells escape from immune system attacks [11]. For example, the limited antitumor effects of cytotoxic T lymphocytes (CTL) were explained by tumor heterogeneity; a subset of tumor cells revealed the down-regulation or absence of human leukocyte antigen (HLA) or targeted antigen proteins [12,13]. Since the growth of solid neoplasms is almost always accompanied with neovascularization [14], which is associated with the expression of vascular endothelial growth factor receptor 1 (VEGFR1) [15] and/or VEGFR2 [16], our vaccine treatment also included the peptides derived from VEGFR1 and VEGFR2 that target neovascular endothelial cells. We selected five HLA-A*2402-restricted peptides derived from RNF43, TOMM34, KOC1, VEGFR1, and VEGFR2 for the clinical trial due to the abundance of the HLA-A*2402 allele in the Japanese population (an allelic frequency of approximately 60%) [17]. We previously performed a phase I study of a combination vaccine treatment for mCRC, and confirmed the safety and the promising potential of our five-peptide-cocktail treatment to improve the prognosis of advanced CRC [18].

FOLFOX (or XELOX) with/without bevacizumab is a widely-used chemotherapy [4] and has been reported to possibly reduce the number of Tregs [19]. We therefore conducted a phase II study of a cancer vaccine consisting of five peptides in combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced CRC.

The purpose of this study was to evaluate the clinical benefit of this cancer vaccine treatment by adding to oxaliplatin-based chemotherapy. Furthermore, we explored a predictive biomarker for its response and for the selection of patients who are likely to exhibit better treatment outcomes following the vaccine treatment. We here demonstrate a promising result of our combination immuno-chemotherapy and predictive biomarkers for immunotherapy.

Patients and methods

Patients and eligibility criteria

Patients were eligible for enrollment when they were ≥ 20 years old with a histologically confirmed advanced CRC, had one or more measurable lesions according to the Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST), were naïve for chemotherapy, had adequate functions of critical organs, had an ECOG performance status (PS) of 0 or 1, and had a life expectancy of ≥ 3 months. The exclusion criteria were CNS involvement, second primary tumors, active infectious disease, any steroid treatment, or any prior peptide vaccination therapies. Written informed consent was obtained from each patient at the time of enrollment. The study was carried out in accordance with the Helsinki declaration on experimentation on human subjects, was approved by the Institutional Ethics Review Boards of Yamaguchi University (H20-102) and each study site, and was registered in the UMIN Clinical Trials Registry as UMIN000001791.

Peptides

The RNF43-721 (NSQPVWLCL) [20], TOMM34-299 (KLRQEVKQNL) [9], KOC1(IMP-3)-508 (KTVNELQNL) [21], VEGFR1-1084 (SYGVLLWEI) [22] and VEGFR2-169 (RFVPDGNRI) [23] peptides restricted with HLA-A*2402 were synthesized by American Peptide Company Inc. (Sunnyvale, CA, USA) according to a standard solid-phase synthesis method, and were purified by reverse-phase high performance liquid chromatography (HPLC). The purity (> 95%) and the identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Endotoxin levels and the bio-burden of these peptides were tested and determined to be within acceptable levels as Good Manufacturing Practice grade for vaccines.

Study design

This phase II, single arm, non-randomized, HLA-A status double-blind study was conducted to assess the efficacy of this combination therapy for first-line treatment for advanced CRC. The therapy consisted of a cocktail of five

therapeutic epitope-peptides in addition to oxaliplatin-containing chemotherapy. Although the peptides used in this study were HLA-A*2402 restricted peptides, all enrolled patients whose HLA-A status were double-blinded were administrated the same regime of peptide cocktail and oxaliplatin-containing chemotherapy.

The cocktail of 3 mg each of five peptides derived from RNF43-721, TOMM34-299, KOC1-508, VEGFR1-1084 and VEGFR2-169, was mixed with 1.5 ml of incomplete Freund's adjuvant (IFA) (Montanide ISA51; Seppic, Paris, France) and administered subcutaneously into the thigh or axilla regions on day 1 of each week for 13 weeks, then the vaccination schedule was reduced to once every 2 weeks. Vaccination was continued even if the disease progressed when the patient wished and a primary doctor who provided additional chemotherapies agreed.

Oxaliplatin-containing regimens were administrated concurrently with the vaccination. Detailed informations of the chemotherapies were described in Additional file 1. Briefly, mFOLFOX6 [24,25] consisted of oxaliplatin (85 mg/m^2) with leucovorin (400 mg/m^2), followed by a FU (400 mg/m^2) bolus, and then 2,400 mg/m^2 continuous infusion with/without bevacizumab (5 mg/kg) [4]. This treatment was repeated every 14 days. XELOX [4] consisted of oxaliplatin (130 mg/m^2) on day 1 followed by oral capecitabine (1,000 mg/m^2) twice daily on days 1 through 14 of a 21-day cycle with/without bevacizumab at a dose of 7.5 mg/kg.

Study objectives

The primary objective was the comparison of the efficacy of the peptide-cocktail plus oxaliplatin-containing regimen on patients with HLA-A*2402 compared with those without HLA-A*2402 by assessing the objective response rate (ORR; complete response (CR) and partial response (PR)). Secondary objectives included comparisons between the two groups for progression free survival (PFS), overall survival (OS), safety, and tolerability. Exploratory end points included the assessments of tumor and blood-based immunological biomarkers.

Assessments

Medical history, physical examination, chest X-ray, ECG, and carcinoembryonic antigen (CEA) measurements were performed within 21 days before starting the treatment. Assessments of vital signs, ECOG performance status, height, weight, and routine blood analysis (hematology and chemistry) were performed within 7 days of starting the treatment. During treatment, physical examination, hematology, and biochemistry analyses were repeated on day 1 of every treatment cycle. Tumor assessments (computed tomography scan, magnetic resonance imaging) were made before starting the study treatment and were repeated every 4 to 8 weeks after the treatment. The RECIST guidelines were used to define all responses. Signs of hematological toxicity and non-hematological toxicity were assessed according to CTCAE during therapy and for 28 days after the last study drug dose.

Immunological biomarkers

We investigated the neutrophil/lymphocyte ratio (NLR) and the peripheral blood lymphocyte counts per the entire white blood cells (lymphocyte-%) before the treatment as predictive markers of the efficacy of the vaccination. NLR and lymphocyte-% were determined immediately at each study site.

Statistical analysis

This study was designed to test the hypothesis that a regime consisting of vaccination plus oxaliplatin-containing



Figure 1 CONSORT diagram. Scheme showing an HLA-A-status double-blind, biologically-randomized phase II study of five therapeutic epitope-peptides combined with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). CRC, colorectal cancer; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine and oxaliplatin; HLA, human leukocyte antigen.

Table 1 Baseline Patient Characteristics

Characteristics		HLA-A*2402 Matched (n = 50)	HLA-A*2402 Unmatched (n = 46)	*p value*
Sex				
	Male	25	24	NS
	Female	25	22	
Age				
	Mean	64.3	63.4	NS
	Standard error	10.9	8	
	Range	36-82	38-77	
Unresectable site				
	Liver	27	35	
	Lung	18	12	
	Dissemination	5	4	NS
	Bone	1	2	
	Lymphnode	13	13	
	Other	5	1	
Number of unresectable sites				
	1	36	30	
	2	9	11	
	3	5	5	
Resection of primary lesion				
	yes	41	43	
	no	9	3	NS
Chemotherapy				
	FOLFOX	48	45	
	XELOX	2	1	NS
	(Bevacizumab)	0	(5)	
Primary minor site				
	Colon	29	36	0.057
	Rectal	21	10	

FOLFOX. infusional fluorouracil. leucovorin. and oxaliplatin: XELOX. capecitabine and oxaliplatin; HLA, human leukocyte antigen; NS. not significant.

chemotherapy is more effective for patients with HLA-A*2402 positive aCRC when compared to those without HLA-A*2402, defining the HLA-A*2402 matched group as the study group and the unmatched group as the control group. Because the response rate of colorectal cancer patients to first line-treatment is generally about 50%, we estimated that a minimum of 40 patients for both arms would be required, assuming a response rate of 50% in the HLA-unmatched control group and 65% in the HLA-matched study group. A two-sided Alpha level of 0.2 and a beta level of 0.5 were assumed.

Response rates were compared by chi-squared test. OS and PFS rates were analyzed by the Kaplan-Meier method and log rank test. For the evaluation of delayed response, we also performed a supplemental analysis of the weighted log-rank tests with the Harrington-Fleming class of weights test for 3 parameter settings ($\rho = 0$ and $\gamma = 0.5$; $\rho = 0$ and $\gamma = 1$; $\rho = 0$ and $\gamma = 2$) [26].

Statistical analyses were performed using SPSS statistics version 20 (SPSS, Chicago, IL, USA) and SAS v9.2. A p value < 0.05 was considered statistically significant.

Results

Patients

Between January 2009 and November 2012, ninety-six patients were enrolled in this trial applying the peptide cocktail treatment in combination with an oxaliplatin-based regimen in 13 hospitals. Fifty patients had at least one allele of HLA-A*2402 and forty-six patients had no HLA-A*2402 allele. The peptide vaccination was administered to all patients. Among the 96 patients enrolled to this trial, 93 patients received mFOLFOX6 and three received XELOX. Five patients were additionally treated with bevacizumab (Figure 1). The baseline characteristics were generally well balanced between the HLA-matched and HLA-unmatched groups, although the proportion of rectal cancer was slightly higher in the HLA-matched group (Table 1). On the cut-off date (25 December, 2013), 87 patients (91%) revealed the progression of the disease with the median OS follow-up period of 38.2 months.

Objective response rate

The ORR was 62.0% and 60.9% in the HLA-matched and HLA-unmatched groups (p = 0.910), respectively (Table 2). The proportions of CR, PR, and SD as well as the disease control rate were 2.0% (1/50), 60.0% (30/50), 32.0% (16/50), and 94.0% (47/50) in the HLA-matched group, respectively, and 0% (0/46), 60.9% (28/46), 37.0% (17/46), 97.8% (45/46) in the HLA-unmatched group, respectively.

Progression free survival

The median PFS was 7.2 months for the HLA-matched group and 8.7 months for the HLA-unmatched group. There was no significant difference between two groups (Figure 2A, P = 0.971). We also performed sub-group analyses using

Table 2 Objective Response rate

HLA-status	HLA-A*2402-matched (n = 50)				HLA-A*2402-unmatched (n = 46)			
Response	CR	PR	SD	PD	CR	PR	SD	PD
Number	1	30	16	3	0	28	17	1
Response rate		31/50	(62.0%)			28/46	(60.9%)	



Figure 2 Progression free survival and overall survival. A and **B**, comparison of progression free survival between HLA-A*2402-mached and -unmatched groups; **A**, all patients; **B**, the patients who received the vaccination for more than 12 months. **C** and **D**, comparison of overall survival between HLA-A*2402-matched and -unmatched groups; **C**, all patients; **D**, patients who received the vaccination for more than 12 months. *MST*, median survival time; HLA, human leukocyte antigen; *M*, months; *the weighted log-rank tests with the Harrington-Fleming class of weights were performed and resulted in, $\rho = 0$, and $\gamma = 0.5$, $p = 0.186$; $\rho = 0$, and $\gamma = 1$, $\rho = 0.080$; $\rho = 0$, and $\gamma = 2$, $\rho = 0.101$.

the patients who received the vaccination for more than 12 months, but there was also no difference between these two groups (Figure 2B, P = 0.946).

Overall survival

The median OS was calculated to be 20.7 months in the HLA-A*2402-matched group and 24.0 months in the unmatched group. There was no significant difference between the two groups (Figure 2C; log-rank test, p = 0.489; Harrington-Fleming method, $\rho = 0$ and $\gamma = 0.5$, $p = 0.186$; $\rho = 0$ and $\gamma = 1$, $p = 0.080$; $\rho = 0$ and $\gamma = 2$, $p = 0.101$). Interestingly, when the patients were able to receive the vaccination for more than 12 months, the OS of the HLA-A*2402-matched group was significantly better than that of the unmatched group (Figure 2D; log-rank test, p = 0.032).

Safety

The most common adverse events (AEs) observed in this trial were neurologic toxicity and hematologic toxicities (Table 3). There was no significant difference in the incidence of AEs including injection site reaction in the two groups. Although the incidences of serious adverse events (SAEs) were almost similar in the two groups, that of neutropenia was relatively higher in the HLA-A*2402-matched group than the unmatched group. Interstitial pneumonia that led to the death was observed in two cases in the HLA-matched group and in one case in the HLA-unmatched group (Table 4).

Immunological biomarkers

NLR is defined as the neutrophil to lymphocyte ratio, and in this study we categorized the patients into two groups (< 3 and ≧ 3) according to the papers reported previously [27]. In this study, NLR of <3.0 was a prognostic marker for the longer survival with peptide cocktail and oxaliplatin-containing chemotherapy (Figure 3A; log-rank test, p = 0.043). The Lymphocyte-% of ≧ 15% was also associated with a long survival (Figure 3B; log-rank test, p = 0.034). Hence, we examined the combined effect of each of these two markers and the HLA types on the clinical efficacy of the vaccination. In patients with a NLR of < 3.0, a significantly longer overall survival was observed in the HLA-A*2402-matched group than the HLA-A*2402-unmatched group (Figure 3C; log-rank test, P = 0.289; Harrington-Fleming method, $\rho = 0$ and $\gamma =$

Table 3 Frequent and Severe Adverse Events (CTCAE version 3.0)

	FOLFOX (n = 89), FOLFOX + Bev (n = 4), XELOX + Bev (n = 1)																			
	HLA-A*2402-matched (n = 50)										HLA-A*2402-unmatched (n = 46)									
	FOLFOX (n = 48), XELOX (n = 2)										FOLFOX (n = 41) + Bev (n = 4), XELOX + Bev (n = 1)									
Adverse Event	1		2		3		4		5		1		2		3		4		5	
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Hand-foot syndrome	0	0	0	0	1	2	0	0	0	0	1	2	0	0	1	2	0	0	0	0
Allergy	4	8	3	6	2	4	0	0	0	0	3	7	4	9	0	0	0	0	0	0
Mucositis	2	4	1	2	1	2	0	0	0	0	2	4	0	0	0	0	0	0	0	0
Nausea/vomiting	5	10	1	2	2	4	0	0	0	0	6	13	2	4	1	2	0	0	0	0
Neurologic toxicity	15	30	10	20	4	8	0		0	0	17	37	10	22	5	11	1	2	0	0
Anorexia	10	20	3	6	4	8	0	0	0	0	10	22	4	9	2	4	0	0	0	0
Diarrhea	3	6	6	12	2	4	0	0	0	0	3	7	0	0	1	2	0	0	0	0
Fatigue/Asthenia	5	10	1	2	2	4	0	0	0	0	5	11	1	2	1	2	0	0	0	0
Fever	2	4	0	0	0	0	0	0	0	0	3	7	2	4	0	0	0	0	0	0
Injection site reaction	18	36	18	36	9	18	0	0	0	0	20	43	17	37	3	13	0	0	0	0
Interstitial pneumonia	0	0	0	0	4	8	0	0	2	4	0	0	0	0	4	9	0	0	1	2
Neutropenia	5	10	10	20	10	20	1	2	0	0	8	17	14	30	2	4	1	2	0	0
Leukopenia	10	20	12	24	1	2	0	0	0	0	12	26	9	20	2	4	0	0	0	0
Thrombocytopenia	17	34	3	6	0	0	0	0	0	0	20	43	2	4	0	0	0	0	0	0
Bilirubin	2	4	2	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
AL-P	11	22	1	2	1	2	0	0	0	0	10	22	1	2	0	0	0	0	0	0
Creatinine	3	6	1	2	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0
Hemoglobin	11	22	5	10	0	0	0	0	0	0	13	28	7	15	0	0	0	0	0	0
Embolism	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0
AST/ALT	12	24	0	0	1	2	0	0	0	0	6	13	1	2	0	0	0	0	0	0

No gastrointestinal perforation nor bleeding wound healing complication was observed. FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine and oxaliplatin; Bev, bevacizumab; AL-P, alkaline phosphatese; AST, aspartete aminotransfarase; ALT, alanine aminotransferase; CTCAE, the Common Terminology Criteria for Adverse Event version 3.0; HLA, Human leukocyte antigen.

0.5, $p = 0.152$; $\rho = 0$ and $\gamma = 1$, $p = 0.064$; $\rho = 0$ and $\gamma = 2$, $p = 0.035$) while this difference was not observed in patients with NLR of $\geqq 3.0$ (log-lank test, $p = 0.962$; Harrington-Fleming method, $\rho = 0$ and $\gamma = 0.5$, $p = 0.495$; $\rho = 0$ and $\gamma = 1$, $p = 0.346$; $\rho = 0$ and $\gamma = 2$, $p = 0.251$). Similarly, in a patient group with a lymphocyte% of $> 15\%$, a longer overall survival was observed in the HLA-A*2402-matched group (Figure 3D; log-lank test, $p = 0.340$; Harrington-Fleming method, $\rho = 0$ and $\gamma = 0.5$, $p = 0.114$; $\rho = 0$ and $\gamma = 1$, $p = 0.051$; $\rho = 0$ and $\gamma = 2$, $p = 0.029$).

Discussion

We performed a phase II study using a cocktail of five epitope peptides, which we previously confirmed its safety, together with oxaliplatin-based chemotherapy. The cocktail contained three peptides derived from three oncoantigens and two peptides targeting VEGFR1 and VEGFR2. This study was an HLA-A-status double-blind, phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as a first-line therapy for advanced

Table 4 Interstitial Pneumonia

HLA genotype	CTCAE grade	Result of DLLT
2402/2402	3	5FU
2402/1101	3	negative
2402/1101	5	negative
2402/0206	3	negative
2402/2603	3	5FU
2402/2602	5	negative
1101/2601	3	5FU
2601/3101	3	5FU
1101/3101	3	5FU
3004/3303	5	not examined
1101/3101	3	not examined

CTCAE, the Common Terminology Criteria for Adverse Event version 3.0; HLA, Human leukocyte antigen; DLTT, drug-induced lymphocyte transformation test; 5FU, 5-fluorouracil.



Figure 3 Biomarkers for the survival and the clinical efficacy of vaccination. Neutrophil/lymphocyte ratio (NLR) < 3.0 and Lymphocyte-% ≧ 15% were considered as indicative factors. **A** and **B**, comparison between the favorite group and others. **C**, comparison of the patients with a NLR of ≧ 3 or a NLR of <3 between the HLA-A*2402-matched and -unmatched groups. **D**, comparison of the patients with Lymphocyte-% ≧ 15% between the HLA-A*2402 positive and negative groups. Lymphocyte (Ly)-%, the percentage of lymphocytes among the peripheral leukocytes; NLR, neutrophil/lymphocyte ratio; HLA, human leukocyte antigen; L-R, log-rank test; *the weighted log-rank tests with the Harrington-Fleming class of weights were performed and resulted in, $\rho = 0$, and $\gamma = 0.5$, $p = 0.152$; $\rho = 0$, and $\gamma = 1$, $p = 0.064$; $\rho = 0$, and $\gamma = 2$, $p = 0.035$; **the Harrington-Fleming tests were resulted in, $\rho = 0$, and $\gamma = 0.5$, $p = 0.495$; $\rho = 0$, and $\gamma = 1$, $\rho = 0.346$; $\rho = 0$, and $\gamma = 2$, $\rho = 0.251$; *** the Harrington-Fleming tests were resulted in, $\rho = 0$, and $\gamma = 0.5$, $p = 0.114$; $\rho = 0$, and $\gamma = 1$, $\rho = 0.051$; $\rho = 0$, and $\gamma = 2$, $\rho = 0.029$.

colorectal cancer (FXV study). In this study, we observed many interesting results.

Firstly, the OS of the HLA-A*2402-matched group was significantly higher compared to that of the unmatched group (log-rank test, p = 0.032) when patients who received the vaccination for more than 12 months (Figure 2D) although no difference in PFS was observed between the two groups (Figures 2B). These results indicated that the additional effect of vaccination on the standard chemotherapy was likely to be slow-acting as this kind of delayed response by the vaccine treatment was indicated in the guidance for therapeutic cancer vaccines released from the US Food and Drug Administration in October, 2011 [28].

Secondly, neutrophil/lymphocyte ratio (NLR) might become a prognostic marker for patients who received the peptide vaccine in combination with standard chemotherapy (Figure 3A, log-rank; p = 0.043), and there was an obvious tail effect for extremely long survival. Then we examined the efficacy of vaccination by comparing HLA-matched group and -unmatched group. In patients with an NLR of < 3.0, a significantly longer survival in the HLA-matched group than the HLA-unmatched group was observed (Figure 3B; log-rank, p = 0.289; Harrington-Fleming, p = 0.035), while this difference was not observed in the two groups with NLR of ≧ 3.0 (log-rank, p = 0.962; Harrington-Fleming, p = 0.251). This result also support the idea that it may be critically important to apply vaccine treatment to patients with better immune status, and NLR might be a one of good predictive markers to select the appropriate patient populations for this type of treatment. A similar result was observed when we analyzed patients with lymphocyte% of ≧ 15%; HLA-matched patients with lymphocyte% of ≧ 15 showed significantly better prognosis than HLA-unmatched patients (Figure 3D; log-rank, p = 0.340; Harrington-Fleming,

p = 0.029). The selection of patients with lower NLR and higher lymphocyte percentage might be useful to the selection of patients who are likely to respond well to vaccine treatment and improve clinical outcomes.

Vaccinations with a cocktail of five peptides together with oxaliplatin-based chemotherapy in metastatic CRC patients were well tolerated, except for relatively frequent cases (11 cases; 11.4%) of pneumonitis (Tables 3 and 4), whose incidence seemed to be higher than previously reported for oxaliplatin-based chemotherapies although no difference was observed between HLA-matched and -unmatched group. Correale et al. reported two cases (5.5%) in 36 patients with advanced gastric cancer treated with gemcitabine plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) [29]. Usui et al. reported that four cases (3.9%) of pneumonitis among 104 Japanese patients treated with oxaliplatin-containing regimes for advanced colorectal cancer [30]. In addition, there have been many case reports of oxaliplatin-related pneumonitis [31-35]. In this study, eleven (11.4%) of 96 patients suffered from severe pneumonitis including three cases with grade 5 pneumonitis. To investigate the possible cause of pneumonitiswe performed drug-induced lymphocyte transformation test (DLTT) for nine patients whose samples were available. Among them, five patients (55.6%) were judged to be positive to fluorouracil alone, and the remaining four patients were negative for all of the antigens tested. Although the size of this study is not large enough to make any conclusion and there is no difference between the two groups, this adverse event should be carefully monitored when we will perform the next-step clinical trial.

Although the efficacy of our peptide vaccine was not clearly demonstrated in this phase II study, the timing of and combination treatment with vaccination might not be optimized, and the sample size was limited. Recently, regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are reported as potent immunosuppressive cells to protect cancer cells from the host immune system [36,37]. Over expression of PD-L1and PD-1 as well as up-regulation of indoleamine-2,3-dioxygenase (IDO) in the tumor microenvironment also inhibit the CTL functions [38]. Hence, to overcome these immune-escape mechanisms, various approaches have been taken in the last decade [39,40]. For example, anti-PD1antibody [41], anti-PD-L1antibody [42], and anti-CTL4 antibody [43] were applied in clinical trials to overcome the suppressive immuno checkpoints, and surprisingly high objective response rates were observed in many types of malignant neoplasm. Small-molecule inhibitors [44] that block IDO enzymatic activity or cyclophosphamide to reduce the number of Tregs [45] were also applied in clinical trials to dissolve the suppressive immunity. For the successful next generation immunotherapy, peptide vaccine should be combined with some agents to modify the immune-suppressive tumor microenvironments.

In conclusion, our cocktail of five therapeutic epitope peptides appears to be effective in a subset of patients, and warrants a randomized phase III study. In the phase III study, biomarkers such as NLR and lymphocyte-% might be useful for assessing the response to the peptide vaccine and for selecting patients likely to have a better treatment outcome with the vaccination.

Conclusions

This phase II cancer vaccine therapy demonstrated that our therapeutic peptides cocktail was likely to be effective in a subset of patients and warrants a randomized phase III study. In the phase III study, predictive biomarkers such as NLR and lymphocyte-% should be used for its response and for selecting patients to have a better treatment outcome with the vaccination.

Additional file

Additional file 1: Summary of the protocol.

Abbreviations

RNF43: Ring finger protein 43; TOMM34: 34 kDa-translocase of the outer mitochondrial membrane; KOC1: insulin-like growth factor–II mRNA binding protein 3; VEGFR: Vascular endothelial growth factor receptor; HPLC: High performance liquid chromatography; CRC: Colorectal cancer; ELISPOT: Enzyme-linked immunospot; PBMC: Peripheral blood mononuclear cells; CTL: Cytotoxic T lymphocytes; RR: Response rates; CR: Complete clinical response; SD: Stable disease; PD: Progressive disease; PFS: Progression free survival; OS: Overall survival; HLA: Human leukocyte antigen; MST: Median overall survival time; ECOG: Eastern cooperative oncology group; RECIST: Response evaluation criteria in solid tumors; TIL: Tumor infiltrating cells; CTCAE: Common terminology criteria for adverse events version3.0; AEs: Adverse events; SAEs: Serious adverse events; DLTT: Drug-induced lymphocyte transformation test; PS: Performance status; IFA: Incomplete freund's adjuvant; CT: Computed tomography; MRI: Magnetic resonance imaging; NLR: Neutrophil/lymphocyte ratio; FOLFOX: Infusional fluorouracil, leucovorin, and oxaliplatin; XELOX: Capecitabine and oxaliplatin, Tregs, regulatory T cells; MDSCs: Myeloid-derived suppressor cells; IDO: Indoleamine-2,3-dioxygenase.

Competing interests

Yusuke Nakamura is a stock holder and a scientific advisor of OncoTherapy Science, Inc. The other authors have no potential conflicts of interest to disclose.

Authors' contributions

SH designed, performed and evaluated clinical study, and wrote the manuscript. YN and MO participated in the design, review and revision of the manuscript. HT, KH, KT, RS, HO, RE, FS, KO, TF, TN, KS, KY, YI, SK, YS, NS, SY, HS, AK, TF, YK and HF assisted to perform clinical study. RT, HT, and TY contributed in the data collection and statistical analysis. All authors participated in the data acquisition and discussion of the manuscript and approved the final manuscript.

Acknowledgements

This study was supported partially by the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) of the Ministry of Education, Culture, Sports, Science and Technology of Japan. The authors would like to thank Prof. Yusuke Nakamura, Dr. Takuya Tsunoda, Dr. Koji Yoshida, Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, for their excellent advice and

cooperation and providing all the peptides. The authors also thank Prof. Koji Kono, Department of Surgery, National University of Singapore, for his excellent managements as The Data and Safety Monitoring Committee of this study.

Author details
[1]Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Japan. [2]Department of Medicine and Surgery, The University of Chicago, Chicago, IL, USA. [3]Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan. [4]Department of Surgery, Kure-Kyosai Hospital, Kure, Japan. [5]Department of Surgery, Ogori Daiichi General Hospital, Yamaguchi, Japan. [6]Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan. [7]Department of Surgery, Kanmon-Medical Center, Shimonoseki, Japan. [8]Department of Surgery, Shimonoseki-Kosei Hospital, Shimonoseki, Japan. [9]Tokyo Women's Medical University Medical Center East, Tokyo, Japan. [10]Department of Pharmacy, Yamaguchi University Hospital, Ube, Japan. [11]Department of Biostatistics, National Cancer Center, Chiba, Japan. [12]Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.

Received: 10 March 2014 Accepted: 16 April 2014
Published: 30 April 2014

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: **Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.** *Int J Cancer* 2010, **127**:2893–2917.
2. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: **FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.** *J Clin Oncol* 2004, **22**:229–237.
3. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L: **Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.** *J Clin Oncol* 2008, **26**:2006–2012.
4. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: **Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.** *J Clin Oncol* 2008, **26**:2013–2019.
5. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: **Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.** *N Engl J Med* 2009, **360**:1408–1417.
6. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: **Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.** *J Clin Oncol* 2010, **28**:4697–4705.
7. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y: **Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression.** *Cancer Res* 2001, **61**:2129–2137.
8. Yagyu R, Furukawa Y, Lin YM, Shimokawa T, Yamamura T, Nakamura Y: **A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer.** *Int J Oncol* 2004, **25**:1343–1348.
9. Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y, Furukawa Y: **Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target.** *Int J Oncol* 2006, **29**:381–386.
10. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y: **Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs.** *Oncogene* 2003, **22**:2192–2205.
11. Rosenberg SA, Yang JC, Restifo NP: **Cancer immunotherapy: moving beyond current vaccines.** *Nat Med* 2004, **10**:909–915.
12. Khong HT, Restifo NP: **Natural selection of tumor variants in the generation of tumor "escape" phenotypes.** *Nat Immunol* 2002, **3**:999–1005.
13. Ryschich E, Notzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Frohlich B, Klar E, Buchler MW, Schmidt J: **Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.** *Clin Cancer Res* 2005, **11**:498–504.
14. Folkman J: **Tumor angiogenesis: therapeutic implications.** *N Engl J Med* 1971, **285**:1182–1186.
15. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U: **Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.** *Proc Natl Acad Sci U S A* 1998, **95**:11709–11714.
16. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A: **High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.** *Cell* 1993, **72**:835–846.
17. Date Y, Kimura A, Kato H, Sasazuki T: **DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese.** *Tissue Antigens* 1996, **47**:93–101.
18. Hazama S, Nakamura Y, Takenouchi H, Suzuki N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K, Shinozaki H, Kamiya A, Furukawa H, Oka M: **A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.** *J Transl Med* 2014, **12**:63.
19. Maeda K, Hazama S, Tokuno K, Kan S, Maeda Y, Watanabe Y, Kamei R, Shindo Y, Maeda N, Yoshimura K, Yoshino S, Oka M: **Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity.** *Anticancer Res* 2011, **31**:4569–4574.
20. Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H: **Ring finger protein 43 as a new target for cancer immunotherapy.** *Clin Cancer Res* 2004, **10**:8577–8586.
21. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H: **Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.** *Cancer Sci* 2007, **98**:1803–1808.
22. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H: **Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.** *Clin Cancer Res* 2006, **12**:5841–5849.
23. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H: **Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2.** *Cancer Res* 2005, **65**:4939–4946.
24. Kato T, Muro K, Yamaguchi K, Bando H, Hazama S, Amagai K, Baba H, Denda T, Shi X, Fukase K, Skamoto J, Mishima H: **Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.** *Ann Oncol* 2012, **23**:933–941.
25. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E: **Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).** *J Clin Oncol* 2012, **30**:3588–3595.
26. Fleming T, Harrington D: *Counting Processes and Survival Analysis.* New York: John Wiley & Sons; 1991.
27. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L: **Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.** *Med Oncol* 2013, **30**:439.
28. U.S. Department of Health and Human Services, Food and Drug Administration: **Guidance for Industry. Clinical Considerations for Therapeutic Cancer Vaccines.** 2011, http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf.
29. Correale P, Fulfaro F, Marsili S, Cicero G, Bajardi E, Intrivici C, Vuolo G, Carli AF, Caraglia M, Del Prete S, Greco E, Gebbia N, Francini G: **Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in**

patients with advanced gastric cancer. *Cancer Chemother Pharmacol* 2005, **56**:563–568.
30. Usui K, Katou Y, Furushima K, Tanaka Y, Tanai C, Ishihara T: **Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.** *Jpn J Clin Oncol* 2011, **41**:498–502.
31. Gagnadoux F, Roiron C, Carrie E, Monnier-Cholley L, Lebeau B: **Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer.** *Am J Clin Oncol* 2002, **25**:388–390.
32. Fuse N, Doi T, Ohtsu A, Takeuchi S, Kojima T, Taku K, Tahara M, Muto M, Asaka M, Yoshida S: **Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.** *Jpn J Clin Oncol* 2007, **37**:434–439.
33. Arevalo Lobera S, Sagastibeltza Marinelarena N, Elejoste Echeberria I, Mele Olive M, Egana Otano L, Basterretxea Badiola L, La Casta Munoa A, Azkue Gabilondo M: **Fatal pneumonitis induced by oxaliplatin.** *Clin Transl Oncol* 2008, **10**:764–767.
34. Pontes LB, Armentano DP, Soares A, Gansl RC: **Fatal pneumonitis induced by oxaliplatin: description of three cases.** *Case Rep Oncol* 2012, **5**:104–109.
35. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Hatakeyama K: **Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX).** *Int J Clin Oncol* 2009, **14**:457–459.
36. Facciabene A, Motz GT, Coukos G: **T-regulatory cells: key players in tumor immune escape and angiogenesis.** *Cancer Res* 2012, **72**:2162–2171.
37. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ: **The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.** *Immunology* 2013, **138**:105–115.
38. Gajewski TF, Schreiber H, Fu YX: **Innate and adaptive immune cells in the tumor microenvironment.** *Nat Immunol* 2013, **14**:1014–1022.
39. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T: **Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.** *Nat Med* 2003, **9**:1477–1483.
40. Pardoll DM: **The blockade of immune checkpoints in cancer immunotherapy.** *Nat Rev Cancer* 2012, **12**:252–264.
41. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: **Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.** *N Engl J Med* 2012, **366**:2443–2454.
42. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: **Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.** *N Engl J Med* 2012, **366**:2455–2465.
43. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M: **Nivolumab plus ipilimumab in advanced melanoma.** *N Engl J Med* 2013, **369**:122–133.
44. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA: **Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.** *Blood* 2010, **115**:3520–3530.
45. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N: **Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.** *Nat Med* 2012, **18**:1254–1261.

doi:10.1186/1479-5876-12-108
Cite this article as: Hazama *et al.*: A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). *Journal of Translational Medicine* 2014 **12**:108.

Lung Cancer 86 (2014) 339–343

Contents lists available at ScienceDirect

Lung Cancer

journal homepage: www.elsevier.com/locate/lungcan

Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer☆

T. Naito[a,*], T. Seto[b], K. Takeda[c], K. Goto[d], I. Okamoto[e], K. Nakagawa[f], T. Ohba[b], H. Murakami[a], T. Takahashi[a], T. Yamanaka[g], N. Yamamoto[h]

[a] Division of Thoracic Oncology, Shizuoka Cancer Center, Japan
[b] Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
[c] Department of Clinical Oncology, Osaka City General Hospital, Japan
[d] Division of Thoracic Oncology, National Cancer Center Hospital East, Japan
[e] Center for Clinical and Translational Research, Kyushu University Hospital, Japan
[f] Department of Medical Oncology, Kinki University School of Medicine, Japan
[g] Department of Biostatistics, Yokohama City University, Japan
[h] Third Department of Internal Medicine, Wakayama Medical University, Japan

ARTICLE INFO

Article history:
Received 1 August 2014
Received in revised form
15 September 2014
Accepted 20 October 2014

Keywords:
Non-small-cell lung cancer
S-1
Leucovorin
Fluoropyrimidine
Chemotherapy
Phase II clinical trial

ABSTRACT

Background: S-1, a novel oral fluoropyrimidine, has potent antitumor activity against non-small-cell lung cancer (NSCLC). Meanwhile, leucovorin enhances the efficacy of 5-fluorouracil by inhibiting thymidylate synthase. Therefore, this phase II clinical trial evaluated the safety and efficacy of S-1 plus leucovorin combination therapy for previously treated patients with NSCLC.
Patients and methods: Patients with stage IIIB or IV NSCLC were prospectively enrolled if they received 1 or 2 prior chemotherapy regimens. S-1 (40–60 mg) and leucovorin (25 mg) were administered together orally twice per day for 7 consecutive days followed by 7 days of rest. This 2-week cycle was repeated for a maximum of 25 cycles until the onset of disease progression or unacceptable adverse events. Endpoints included objective tumor response, progression-free survival, overall survival, and safety.
Results: Among 33 patients, 6 (18.2%), 14 (42.4%), and 11 (33.3%) had partial response, stable disease, and progressive disease, respectively. Median progression-free and overall survival times were 3.5 and 11.7 months, respectively. The common grade 3 toxicities included stomatitis (18.2%), anorexia (12.1%), and neutropenia (9.1%). One patient had pneumatosis cystoides intestinalis, and another experienced paralytic ileus. There were no treatment-related deaths.
Conclusions: S-1 plus leucovorin combination therapy demonstrated promising efficacy and an acceptable toxicity profile in previously treated patients with NSCLC.

1. Introduction

Lung cancer is one of the leading causes of death worldwide [1]. Approximately 80% of lung cancers result from non-small-cell histology, and most patients present with locally advanced stage III or metastatic stage IV disease at diagnosis. Advanced non-small-cell lung cancer (NSCLC) generally results in poor outcomes, except for a small patient population with specific genetic alterations conferring susceptibility to specific molecular targeted treatments [2]. The results of phase III trials for previously treated patients with NSCLC indicate that single-agent chemotherapy with docetaxel, pemetrexed, or erlotinib as the standard chemotherapy regimen for recurrent NSCLC results in a response rate of 8.8–9.1%, median survival time of 6.7–8.3 months, and 1-year survival rate of 30–31% [3,4]. S-1 (Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) is a capsule preparation comprising tegafur, an oral 5-fluorouracil (5-FU) pro-drug, 5-chloro-2,4-dihydroxypyridine (CDHP), and oteracil potassium at a molar ratio of 1.0:0.4:1.0. CDHP is a reversible competitive inhibitor of dihydropyrimidine dehydrogenase, an enzyme for 5-FU degradation. Meanwhile, oteracil potassium is a reversible competitive inhibitor of orotate phosphoribosyl transferase, an enzyme for 5-FU phosphoribosylation in the gastrointestinal mucosa [5]. The antitumor activity of S-1 against

☆ **Clinical Trials Registry Number**: UMIN000004568.

* Corresponding author at: Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan.
Tel.: +81 55 989 5222; fax: +81 55 989 5634.
E-mail address: t.naito@scchr.jp (T. Naito).

http://dx.doi.org/10.1016/j.lungcan.2014.10.010
0169-5002/

NSCLC has been proven in several clinical trials. First-line treatment of S-1 combined with platinum showed favorable outcomes in 2 phase III trials for metastatic NSCLC [6,7]. Chemoradiation with S-1 plus cisplatin also showed promising results in locally advanced NSCLC [8,9]. In second- or third-line settings, several phase II trials demonstrate promising antitumor activity of S-1 monotherapy for previously treated patients with advanced NSCLC [10–13]. The addition of leucovorin increases the intracellular concentration of reduced folates, thus stabilizing the 5-fluorodeoxyuridine monophosphate/thymidylate synthase enzyme complex, providing the biochemical rationale for adding leucovorin to 5-FU and tegafur chemotherapy regimens [14,15]. An in vivo study of S-1 plus leucovorin treatment using xenograft mouse models of human colorectal cancer cells demonstrated that leucovorin might improve the antitumor activity of S-1 [16]. A phase II clinical trial of S-1 plus oral leucovorin for chemotherapy-naïve patients with metastatic colorectal cancer recently demonstrated promising efficacy [17]. In addition, this treatment might improve the convenience of cancer care because of the combination of oral medicines. Accordingly, the present phase II study evaluated the safety and efficacy of S-1 plus leucovorin combination therapy in previously treated patients with advanced NSCLC.

2. Methods

2.1. Patients

This was an open-labeled, multicenter, single-arm, phase II study. Patients were enrolled from the following 5 institutions: Kinki University, the National Cancer Center Hospital East, the National Kyushu Cancer Center, Osaka City General Hospital, and the Shizuoka Cancer Center. The eligibility criteria were as follows: (1) histologically and/or cytologically proven stage IIIB or IV NSCLC with at least 1 measurable lesion; (2) 1 or 2 previous cytotoxic chemotherapy regimens; *EGFR* tyrosine kinase inhibitors and adjuvant chemotherapy were not counted as a prior treatment; and (3) Eastern Cooperative Oncology Group performance status 0–1 and adequate organ function. Patients were excluded if they had received systemic chemotherapy or thoracic radiation within the previous 4 weeks, radiation to extrathoracic lesions within the previous 2 weeks, or previous treatment with fluoropyrimidine agents. Patients with serious medical conditions including other malignancies, symptomatic brain metastases, psychiatric disorders, active infectious diseases, and active ischemic heart disease were also excluded. A data and safety monitoring board monitored the trial on an ongoing basis. The protocol, protocol amendments, informed consent, and other documents pertaining to the study were approved by the institutional review board of each participating center. The first and last authors vouch for the accuracy and completeness of the data and analyses reported as well as the fidelity of the report to the study protocol. This trial is registered on the clinical trials site of the University Hospital Medical Information Network Clinical Trials Registry in Japan (registration number: UMIN000004568).

2.2. Treatment plan

The dose of S-1 (capsules containing tegafur 20 or 25 mg) was determined according to body surface area as follows: 40, 50, and 60 mg for <1.25, 1.25–1.50, and ≥1.50 m^2, respectively.

Leucovorin (25-mg tablets) was administered at a fixed dose of 25 mg. S-1 and leucovorin were administered together orally twice per day for 7 consecutive days followed by 7 days of rest; this 2-week cycle was repeated for a maximum of 25 cycles until the onset of disease progression or unacceptable adverse events.

Table 1
Patient characteristics.

Characteristics	*N* = 33	%
Gender (male:female)	25:8	
Age, median (range)	65 (27–74)	
ECOG-PS 0	13	39.4
1	20	60.6
Histology		
Adenocarcinoma	26	78.8
Squamous cell carcinoma	4	12.1
Large cell carcinoma	2	6.1
Pleomorphic carcinoma	1	3.0
Stage		
IIIB	5	15.2
IV	28	84.8
No. of prior chemotherapy		
1 Regimen	11	33.3
2 Regimens	19	57.6
3 Regimens	3	9.1

The dose of S-1 could be decreased by 2 levels to a minimum dose of 20 mg twice daily in the event of following toxicities: grade 4 neutropenia or non-hematologic toxicity, or grade 3 thrombocytopenia, diarrhea, stomatitis, or skin rash. The dose of leucovorin was not decreased.

2.3. Study assessment

Tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1, and computed tomography scans were performed every 4–6 weeks. If a patient responded, response was confirmed through tumor assessments at least 4 weeks after the first documentation of a response. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Physical examination, chest radiograph, laboratory chemistry, and hematology were performed at baseline and on day 1 of each cycle.

2.4. Statistical analysis

The primary endpoint of the study was the antitumor activity of S-1 plus leucovorin assessed according to the overall response rate (ORR) including complete response (CR) and partial response (PR). The secondary endpoints were overall survival (OS), progression-free survival (PFS), and safety profile. We defined acceptable and unacceptable ORRs as 20% and 5%, respectively. The sample size was determined to be 30 on the basis of the exact binomial probability distribution of Southwest Oncology Group 2-stage design with a statistical power ($1 - \beta$) of 80% and significance level (α) of 5%. All analyses were performed using JMP version 9.0 for Windows (SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Patient characteristics

From December 2010 through September 2011, a total of 33 patients (median age: 65 years, range: 27–74 years) who met the inclusion criteria were enrolled (Table 1). The majority of the patients had stage IV disease (28 patients, 84.8%), including 5 patients (15.2%) with postoperative relapse. Histopathological diagnoses included adenocarcinoma, squamous-cell carcinoma, large-cell carcinoma, and pleomorphic carcinoma in 26, 4, 2, and 1 patient, respectively. An activating *EGFR* gene mutation was assessed in 26 patients, 5 of whom had a mutant gene. Regarding prior chemotherapy, 1 patient had received platinum-based chemoradiotherapy, and 2 patients had received gefitinib



Fig. 1. (A) Kaplan Meier survival curve of overall survival and (B) Kaplan Meier survival curve of progression free survival.

as a first-line treatment. The remaining 30 patients had received platinum-based chemotherapy with or without bevacizumab as a first-line treatment. A total of 23 patients had received second-line or more chemotherapy before study entry.

3.2. Treatment delivery

A total of 255 treatment cycles were administered to patients. The median number of treatment courses was 6 (range: 1–25). The median treatment period was 2.5 months (95% confidential interval [CI]: 1.1–4.0 months). Dose reduction and treatment interruption were required in 13 (39.4%) and 6 (18.2%) patients, respectively. The reasons for treatment withdrawal were disease progression in 22 (66.7%), toxicities in 4 (12.1%), protocol completion in 3 (9.1%), and patient preference in 4 (12.1%). The median total doses per 6 weeks for S-1 and leucovorin were 2100 mg (range: 840–2520 mg) and 1050 mg (range: 350–1050 mg), respectively. The median relative dose intensity for the first 6 weeks for S-1 and leucovorin were 82.5% (95% CI: 74.8–90.3%) and 84.5% (95% CI: 76.8–92.2%), respectively.

3.3. Efficacy

The objective tumor response (the primary endpoint) was assessed by independent evaluators in all 33 patients. One woman was considered unevaluable for tumor response because she asked to discontinue the study treatment after 1 course because of grade 1 mucositis and declined radiological assessment. Among the remaining 32 patients, 0, 6, 15, and 11 had complete response, partial response, stable disease, and progressive disease, respectively. The response rate was 18.2% (95% CI: 7.0–35.5%), and the disease control rate was 63.6% (95% CI: 45.1–79.6%, Table S1). Although the patients had heterogeneous background characteristics including pathological diagnosis and the number of previous treatments, most patients experienced tumor shrinkage or stabilization during the study period (Fig. S1). All 33 patients were evaluable for the OS and PFS, and their median follow-up duration was 17.9 (95% CI: 14.1–20.2) months. The cutoff date for analysis was November 6, 2012. At the time of analysis, 11 (33.3%), 3 (9.1%), and 0 (0%) patients were alive, free of progression, and on study treatment, respectively. Median survival time was 11.7 months (95% CI: 6.1–16.9 months) and the 1-year survival rate was 45.5% (95% CI: 29.6–62.3%, Fig. 1A). Median PFS was 3.5 months (95% CI: 2.4–5.1 months, Fig. 1B), and the median time to treatment failure was 2.5 months (95% CI: 1.1–4.0 months). A Comparison of efficacy with S-1 monotherapy showed a relatively better efficacy profile in our study treatment (Table 2). A comparison of efficacy among histology types was also summarized in Table S2. A total of 2 out of 26 patients with adenocarcinoma (7.7%) and 4 out of 7 patients with non-adenocarcinoma (57.1%) showed partial response ($p = 0.2233$, Fisher's exact test) including 2 squamous carcinoma, 1 pleomorphic carcinoma, and 1 large cell carcinoma. Median OS was 10.3 in patients with adenocarcinoma and not reached in non-adenocarcinoma ($p = 0.0505$, log-rank test). A total of 19 patients (57.6%) received additional treatments after the study treatment, including docetaxel, erlotinib with or without investigational drugs in clinical trials, gemcitabine, pemetrexed, and palliative radiation therapy in 5, 5, 4, 2, and 3 patients, respectively.

3.4. Safety and adverse events

Safety data from all 33 patients are shown in Table 3. All toxicities with an incidence ≥50% included anemia (93.9%), hypoalbuminemia (87.9%), anorexia (84.8%), stomatitis (72.7%), fatigue (60.6%), pigmentation (57.6%), nausea (54.5%), and leukocytopenia (51.5%). Grade 3 toxicity occurred in 15 patients (45.5%). Grade 3 toxicities with an incidence ≥10% included stomatitis (18.2%) and anorexia (12.1%). One patient each had pneumatosis cystoides intestinalis (grade 3) and paralytic ileus (grade 3); both toxicities improved as a result of interrupting treatment and subsequently resuming treatment with a reduced dose. There were no grade 4 toxicities, febrile neutropenia, or interstitial lung disease. The dose was reduced at least once in 13 patients (39.4%), mainly because of stomatitis and anorexia. Rest periods were prolonged in 15 patients (45.5%), mainly because of persistent stomatitis, anorexia, and fatigue. The median number of treatment courses until the worst grade of stomatitis, anorexia, fatigue, diarrhea, and rash was 2, 1, 3, 2, and 1, respectively. There were no treatment-related deaths. A Comparison of ≥grade 3 adverse events with S-1 monotherapy showed increased percentage of anorexia, stomatitis, and neutropenia in our study treatment (Table 3).

4. Discussion

This multicenter phase II clinical trial demonstrates the efficacy and safety of S-1 plus oral leucovorin combination therapy for previously treated patients with NSCLC. The results show that the treatment has promising antitumor activity, with an objective response rate of 18.2%, which meets the primary endpoint of this

Table 2
Comparison of efficacy with S-1 monotherapy.

Efficacy	Our study	Totani et al. [12]	Shiroyama et al. [11]	Govindan et al. [10]	Wada et al. [13]
N	33	48	44	57	30
Treatment line	2nd or 3rd	2nd	2nd	2nd	≥2nd
Response rate (%)	18.2	12.5	13.6	7.1	26.7
Disease control rate (%)	63.6	39.6	77.3	55.3	70.0
Median PFS (months)	3.5	2.5	4.2	2.9	3.1
Median OS (months)	11.7	8.2	16.4	7.3	11.2
1-year survival rate (%)	45.5	29.6	60.3	31.6	43.3

PFS, progression-free survival; OS, overall survival.

study. The treatment was safe and tolerable for all patients, and there were no grade 4 toxicities or treatment-related deaths.

Leucovorin is a biochemical modulator of 5-FU that stabilizes the inhibitory ternary complex formed between thymidylate synthase and the active metabolite of 5-FU, 5-fluorodeoxyuridylate. A meta-analysis of advanced colorectal cancer cases revealed that leucovorin improves response rates and OS when combined with 5-FU in comparison to 5-FU alone [18]. The 5-FU/leucovorin-based regimens such as 5-FU/leucovorin plus oxaliplatin and/or irinotecan are standard treatments for metastatic colorectal cancer [19]. The role of S-1 in the treatment of other solid tumors including gastric, colorectal, biliary tract, pancreatic, and lung cancers has recently been increasing [20–22]. The antitumor activity of S-1 against NSCLC has been proven in several clinical trials [6–8]. There are several reports of S-1 monotherapy as a second-line or subsequent-line treatment for previously treated NSCLC [10–13], with response rates ranging from 7.1% to 26.7%, median PFS from 2.5 to 4.2 months, median survival time from 8.2 to 16.4 months, and the 1-year survival rate from 29.6% to 60.3% (Table 2). Relatively low incidences of severe toxicities (i.e., grade 3 or 4) were reported, and the treatment was considered to be well tolerated.

The present study is the first report of the efficacy and safety of S-1/leucovorin combination therapy for advanced NSCLC. The results revealed a relatively high response rate and long PFS, indicating that leucovorin potentiates the antitumor activity of S-1. However, regarding safety, the incidence of toxicity was higher with S-1/leucovorin combination therapy in the present study than with S-1 monotherapy in previous studies; approximately 45% of the present patients experienced grade 3 toxicities such as stomatitis, anorexia, and neutropenia in comparison to <20% of patients receiving S-1 monotherapy. Similarly, in the clinical trial of S-1/leucovorin combination therapy for colorectal cancer, treatment resulted in a relatively high incidence of non-hematologic toxicities. In the original 4-week regimen, in which S-1/leucovorin was administered for 2 weeks followed by 2 weeks of rest, grade 3 toxicities occurred in 55% of patients, including diarrhea, anorexia, stomatitis, and neutropenia in 32%, 21%, 20%, and 14%, respectively. As a result, 59% of the patients in that study required dose reduction, and 54% required a prolonged rest period [17]. A modified less-toxic treatment schedule in which S-1/leucovorin is administered for 1 week followed by 1 week of rest was recently proposed in a multicenter international phase II study conducted in Japan and China [23]. This regimen resulted in decreased occurrence of severe toxicities associated with this combination therapy without reducing relative dose intensity or efficacy. Grade 3 diarrhea, anorexia, stomatitis, and neutropenia occurred in 8.3%, 2.8%, 8.3%, and 9.7% of patients, respectively. Although we used the latter treatment schedule (i.e., 1 week on/1 week off), the incidences of stomatitis (18.2%) and anorexia (12.1%) were slightly higher. This might be due to the differences in patient characteristics between studies: our patients were administered 1 or more chemotherapeutic regimens, while the other study included

Table 3
Treatment-related adverse events.

Adverse events, *N* (%)[a]	Any grade	Grade 2	Grade 3	Reference[b] ≥Grade 3 in S-1 monotherapy (%)
Non-hematologic				
Anorexia	28(84.8)	15(45.5)	4(12.1)	2.1–7.1
Stomatitis	24(72.7)	10(30.3)	6(18.2)	0.0–3.6
Fatigue	20(60.6)	11(33.3)	1(3.0)	0.0–12.5
Hyperpigmentation	19(57.6)	4(12.1)	–	–
Nausea	18(54.5)	9(27.3)	–	0.0–5.4
Vomiting	12(36.4)	5(15.2)	0(0.0)	0.0–1.8
Diarrhea	15(45.5)	5(15.2)	1(3.0)	0.0–21.4
Constipation	13(39.4)	3(9.1)	0(0.0)	0.0
Skin rash	13(39.4)	5(15.2)	1(3.0)	1.8–2.1
Alopecia	5(15.2)	–	–	–
Hematologic				
Anemia	31(93.9)	14(42.4)	1(3.0)	1.8–4.5
Hypoalbuminemia	29(87.9)	7(21.2)	0(0.0)	0.0
Leukocytopenia	17(51.5)	7(21.2)	2(6.1)	0.0–4.5,
Hyponatremia	14(42.4)	0(0.0)	2(6.1)	0.0
Hypocarcemia	13(39.4)	2(6.1)	0(0.0)	0.0
Neutropenia	10(30.3)	6(18.2)	3(9.1)	2.1–4.5
Thrombocytopenia	9(27.3)	0(0.0)	0(0.0)	0.0
Hypokalemia	6(18.2)	0(0.0)	2(6.1)	0.0
Alkaline phosphatase increased	6(18.2)	2(6.1)	0(0.0)	0.0
Hyperkalemia	6(18.2)	0(0.0)	0(0.0)	0.0
Total bilirubin increased	6(18.2)	0(0.0)	0(0.0)	0.0

[a] No grade 4 or more toxicity was reported.
[b] The data was a summary of Refs. [10–13].

only chemotherapy-naïve colorectal cancer patients. In addition, the median age was higher (65 vs. 60 years) and the percentage of ECOG-PS grade 0 was lower (39.4% vs. 54.9%) in our patients than that in the previous study. However, in the present study, all of the toxicities were easily manageable by routine supportive care with short treatment interruption, and most of the patients were able to resume treatment with or without dose reduction.

A major limitation of this study is a small study population comprising exclusively Japanese patients. Accordingly, the toxicity profile of S-1 is reported to differ by ethnicity [10,24]. The primary dose-limiting toxicity of S-1 in American and European clinical trials was gastrointestinal toxicity including diarrhea and nausea/vomiting [25,26], whereas that in Japanese clinical trials was hematological toxicity [27]. Because S-1/leucovorin combination therapy resulted in a relatively high incidence of gastrointestinal toxicities, caution should be exercised when administering this treatment to patients of different ethnicities, especially American and European populations.

In conclusion, this phase II study demonstrates that S-1 with oral leucovorin combination therapy has promising antitumor activity and is well tolerated in previously treated patients with NSCLC. Nevertheless, further large-scale Phase III clinical trials comparing the efficacy of S-1/leucovorin combination therapy with current standard treatment are required to confirm the benefits of this treatment.

Funding

This work was supported by the Fuji pharma valley center.

Conflict of interest statement

None declared.

Acknowledgements

We thank M. Ishi, Y. Yoshizawa, and T. Soga of the Fuji pharma valley center for their data-monitoring and quality control. We are grateful to N. Boku, T. Yoshino, and J. Sasaki for their kind advice as an independent safety monitoring committee and A. Tamiya and S. Miura who carried out the external review board.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.lungcan.2014.10.010.

References

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30.
[2] Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380–8.
[3] Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589–97.
[4] Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123–32.
[5] Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53(17):4004–9.
[6] Katakami N, Gemma A, Sakai H, Kubota K, Nishio M, Inoue A, et al. Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701). In: Proceeding of the 2012 ASCO Annual Meeting J Clin Oncol. 2012 (suppl; abstr 7515).
[7] Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan Oncology Group Study. J Clin Oncol 2010;28(36):5240–6.
[8] Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, et al. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). J Thorac Oncol 2011;6(12):2069–75.
[9] Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 2009;101(2):225–31.
[10] Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, et al. Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6(4):790–5.
[11] Shiroyama T, Komuta K, Imamura F, Hirashima T, Kijima T, Tachibana I, et al. Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer 2011;74(1):85–8.
[12] Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, et al. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009;64(6):1181–5.
[13] Wada M, Yamamoto M, Ryuge S, Nagashima Y, Hayashi N, Maki S, et al. Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012;69(4):1005–11.
[14] Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981;41(9 PT 1):3288–95.
[15] Houghton JA, Maroda SJ, Phillips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 1981;41(1):144–9.
[16] Tsukioka S, Uchida J, Tsujimoto H, Nakagawa F, Sugimoto Y, Oka T, et al. Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: evidence from a xenograft model of folate-depleted mice. Mol Med Rep 2009;2(3):393–8.
[17] Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2010;21(4):766–71.
[18] Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22(18):3766–75.
[19] Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30.
[20] Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9(3):215–21.
[21] Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, et al. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 2013;71(4):973–9.
[22] Sudo K, Ishihara T, Hirata N, Ozawa F, Ohshima T, Azemoto R, et al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemother Pharmacol 2014;73(2):389–96.
[23] Denda T, Li J, Xu R, Xu J, Ikejiri K, Shen L, et al. Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China. In: Proceeding of the 2013 Gastrointestinal Cancers Symposium J Clin Oncol. 2012 (suppl 34; abstr 528).
[24] Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26(13):2118–23.
[25] Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002;8(7):2116–22.
[26] van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18(14):2772–9.
[27] Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, et al. [Phase I study of S-1, S-1 Study Group]. Gan To Kagaku Ryoho 1997;24(15):2253–64.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring *EGFR* mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato, Makoto Nishio, Koichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Kosei Tajima, Ryosuke Harada, Masahiro Fukuoka, Nobuyuki Yamamoto

Lancet Oncol 2014; 15: 1236–44
Published Online August 28, 2014
http://dx.doi.org/10.1016/S1470-2045(14)70381-X
This online publication has been corrected. The corrected version first appeared at thelancet.com/oncology on September 29, 2014

See Comment page 1184

National Kyushu Cancer Center, Fukuoka, Japan (T Seto MD); Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan (T Kato MD); The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan (M Nishio MD); National Cancer Center Hospital East, Chiba, Japan (K Goto MD); Kinki-chuo Chest Medical Center, Osaka, Japan (S Atagi MD); Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan (Y Hosomi MD); National Cancer Center Hospital, Tokyo, Japan (Noboru Yamamoto MD); Aichi Cancer Center, Aichi, Japan (T Hida MD); Miyagi Cancer Center, Miyagi, Japan (M Maemondo MD); Kinki University Faculty of Medicine, Osaka, Japan (Prof K Nakagawa MD); Tokyo Medical University Hospital, Tokyo, Japan (S Nagase MD); Kyushu University Hospital, Fukuoka, Japan (I Okamoto MD); National Cancer Center, Chiba, Japan (T Yamanaka PhD); Chugai Pharmaceutical Co Ltd, Tokyo, Japan (K Tajima MSc, R Harada BS); Izumi Municipal Hospital, Osaka, Japan (M Fukuoka MD); and Wakayama Medical University, Wakayama, Japan (Prof Nobuyuki Yamamoto MD)

Summary

Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating *EGFR* mutation-positive non-small-cell lung cancer (NSCLC), median progression-free survival has been extended to about 12 months. Nevertheless, new strategies are needed to further extend progression-free survival and overall survival with acceptable toxicity and tolerability for this population. We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating *EGFR* mutation-positive disease.

Methods In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating *EGFR* mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival, as determined by an independent review committee. Randomisation was done with a dynamic allocation method, and the analysis used a modified intention-to-treat approach, including all patients who received at least one dose of study treatment and had tumour assessment at least once after randomisation. This study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-111390.

Findings Between Feb 21, 2011, and March 5, 2012, 154 patients were enrolled. 77 were randomly assigned to receive erlotinib and bevacizumab and 77 to erlotinib alone, of whom 75 patients in the erlotinib plus bevacizumab group and 77 in the erlotinib alone group were included in the efficacy analyses. Median progression-free survival was 16·0 months (95% CI 13·9–18·1) with erlotinib plus bevacizumab and 9·7 months (5·7–11·1) with erlotinib alone (hazard ratio 0·54, 95% CI 0·36–0·79; log-rank test p=0·0015). The most common grade 3 or worse adverse events were rash (19 [25%] patients in the erlotinib plus bevacizumab group *vs* 15 [19%] patients in the erlotinib alone group), hypertension (45 [60%] *vs* eight [10%]), and proteinuria (six [8%] *vs* none). Serious adverse events occurred at a similar frequency in both groups (18 [24%] patients in the erlotinib plus bevacizumab group and 19 [25%] patients in the erlotinib alone group).

Interpretation Erlotinib plus bevacizumab combination could be a new first-line regimen in *EGFR* mutation-positive NSCLC. Further investigation of the regimen is warranted.

Funding Chugai Pharmaceutical Co Ltd.

Introduction

Lung cancer is a leading cause of death worldwide; it is the primary cause of cancer deaths in men and the secondary cause in women.[1] Most patients with lung cancer have non-small-cell lung cancer (NSCLC) and a clinically significant proportion of patients have activating mutations of *EGFR*.[2] In this subgroup of patients, EGFR tyrosine-kinase inhibitors have consistently led to better outcomes than has standard chemotherapy.[3–6] Erlotinib and gefitinib have been shown to prolong progression-free survival compared with chemotherapy in several phase 3 trials.[7–10] Unfortunately, most patients with NSCLC with activating *EGFR* mutations who are given EGFR tyrosine-kinase inhibitors eventually develop resistance and relapse within about 1 year of initiation of treatment.[5,7–11] To improve outcomes, the foundation treatment of EGFR tyrosine-kinase inhibitors should be built on through investigation of biologically synergistic combinations.

The anti-angiogenic monoclonal antibody bevacizumab targets the VEGF signalling pathway and has been shown to provide additional efficacy when used in combination with first-line platinum-based chemotherapy in several trials in non-squamous NSCLC.[12–14] The combination of erlotinib and bevacizumab has the potential to prolong progression-free survival in unselected populations of patients with NSCLC.[15,16] In a subgroup analysis of *EGFR*

mutation-positive participants in the phase 3 BeTa study of second-line treatment of NSCLC (12 patients treated with erlotinib and bevacizumab and 18 with erlotinib alone), median progression-free survival with erlotinib plus bevacizumab in patients with *EGFR* mutation-positive disease was substantially higher than with erlotinib alone (17·1 months *vs* 9·7 months).[16,17] However, this analysis was post-hoc and *EGFR* mutation status was not a prespecified stratification factor in this trial. Because of this limitation, we undertook this phase 2 trial to examine the combination of erlotinib and bevacizumab in patients with *EGFR* mutation-positive NSCLC.

Methods

Study design and patients

JO25567 was a randomised, open-label, multicentre, phase 2 study in patients with stage IIIB/IV (according to the 7th edition of the General Rule for Clinical and Pathological Record of Lung Cancer[18]) or recurrent NSCLC with activating *EGFR* mutations. Patients were enrolled from 30 centres across Japan.

Eligible patients had histologically or cytologically (excluding sputum cytology) confirmed stage IIIB/IV or postoperative recurrent non-squamous NSCLC with activating *EGFR* mutation (either exon 19 deletion or Leu858Arg mutation). Tumour samples were screened for *EGFR* mutation by PCR-based hypersensitive *EGFR* mutation testing in local laboratories, according to standard testing practices. Other criteria included age 20 years or older when giving informed consent; Eastern Cooperative Oncology Group performance status 0 or 1; adequate haematological, hepatic, and renal function; and life expectancy 3 months or more at the time of registration. No previous chemotherapy for advanced disease was allowed, but postoperative adjuvant or neoadjuvant therapy of 6 months or more previously was allowed. Previous radiotherapy was also allowed, but only for non-lung lesions. Patients had to have one or more measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

Major exclusion criteria included confirmation of Thr790Met mutation, presence of brain metastases, history or presence of haemoptysis or bloody sputum, any coagulation disorder, tumour invading or abutting major blood vessels, coexistence or history of interstitial lung disease, and previous receipt of EGFR inhibitors or VEGF receptor inhibitors.

This study was done in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was reviewed and approved by the institutional review boards of the participating institutions (appendix p 10), and written informed consent was obtained from all patients.

Randomisation and masking

Patients were randomly assigned (1:1) to receive either erlotinib plus bevacizumab or erlotinib alone with a dynamic allocation method. Central randomisation was done by a clinical research organisation (EPS Corporation, Tokyo, Japan). Patients were stratified according to sex (men *vs* women), disease stage (stage IIIB *vs* stage IV *vs* postoperative relapse), smoking history (never smokers or former light smokers *vs* others), and type of *EGFR* mutation (exon 19 deletion *vs* Leu858Arg mutation). All patients and investigators were unmasked to treatment allocation.

Procedures

Patients assigned to the erlotinib plus bevacizumab group received bevacizumab 15 mg/kg by intravenous infusion on day 1 of a 21-day cycle and erlotinib orally once daily at 150 mg/day, starting from day 1 of cycle 1. Patients in the erlotinib alone group received erlotinib orally once a day at 150 mg/day. Patients remained on treatment until disease progression or unacceptable toxicity. Changes to dose of erlotinib or bevacizumab because of adverse events were allowed, as per the protocol. The dose of bevacizumab was not to be reduced except when dose adjustment was needed because of change in bodyweight. Dose reduction of erlotinib was allowed for up to two doses (100 mg/day and 50 mg/day) in a stepwise decrease. After two steps of dose reduction, erlotinib was discontinued. Patients who required suspension of erlotinib for more than 3 weeks consecutively, or of bevacizumab for more than 6 weeks from the date of previous administration, were discontinued from study treatment. In the erlotinib plus bevacizumab group, if either drug was discontinued, the other could be

Correspondence to:
Prof Nobuyuki Yamamoto, Wakayama Medical University, 811-1, Kimiidera, Wakayama-shi, Wakayama 641-8509, Japan
nbyamamo@wakayama-med.ac.jp

See Online for appendix



Figure 1: **Trial profile**